AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25881049 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfuse if haemoglobin concentration <9 g/dl)
Number of subjects: 2000
Study 24018463 — intervention group
Group type: EXPERIMENTAL
Intervention: S-PD (metal-ceramic screwed partial dentures)
Number of subjects: 131
Study 24018463 — intervention group
Group type: EXPERIMENTAL
Intervention: S-CD (metal-ceramic screwed complete dentures)
Number of subjects: 131
Study 24018463 — intervention group
Group type: COMPARATOR
Intervention: HP (fixed-detachable hybrid prostheses)
Number of subjects: 131
Study 21518684 — intervention group
Group type: EXPERIMENTAL
Intervention: HemCon pad
Number of subjects: 136
Study 21518684 — intervention group
Group type: COMPARATOR
Intervention: Regular pad
Number of subjects: 136
Study 18053055 — intervention group
Group type: EXPERIMENTAL
Intervention: CryoHist
Number of subjects: 75
Study 18053055 — intervention group
Group type: COMPARATOR
Intervention: Cryocup
Number of subjects: 75
Study 18053055 — intervention group
Group type: COMPARATOR
Intervention: Miami Special
Number of subjects: 75
Study 18053055 — intervention group
Group type: EXPERIMENTAL
Intervention: CryoHist (for large specimens >2.5 cm)
Number of subjects: 75
Study 17042886 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day) with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 82
Study 17042886 — intervention group
Group type: COMPARATOR
Intervention: Placebo with lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 82
Study 12776851 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent ratings
Number of subjects: 60
Study 12776851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent self-ratings
Number of subjects: 60
Study 10902861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric trimaltol (four different pharmaceutical formulations)
Number of subjects: 12
Study 10902861 — intervention group
Group type: COMPARATOR
Intervention: Normal colorimetry
Number of subjects: 12
Study 9068464 — intervention group
Group type: EXPERIMENTAL
Intervention: OBTM‐2 (bismuth subcitrate 240 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 2 days)
Number of subjects: 100
Study 9068464 — intervention group
Group type: COMPARATOR
Intervention: OBTM‐7 (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg four times daily for 1 wk)
Number of subjects: 100
Study 9068464 — intervention group
Group type: EXPERIMENTAL
Intervention: OBTM‐2
Number of subjects: 100
Study 9068464 — intervention group
Group type: COMPARATOR
Intervention: OBTM‐7
Number of subjects: 100
Study 8453956 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-felodipine (20 mg solution p.o.)
Number of subjects: 12
Study 8453956 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-nitrendipine (20 mg solution p.o.)
Number of subjects: 12
Study 8453956 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg solution p.o.)
Number of subjects: 12
Study 29228315 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w)
Number of subjects: 336
Study 29228315 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w
Number of subjects: 336
Study 27128532 — intervention group
Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor (22.5 mg BID for 7 days)
Number of subjects: 30
Study 27128532 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (75 mg QD for 7 days)
Number of subjects: 30
Study 27128532 — intervention group
Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor
Number of subjects: 30
Study 27128532 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 30
Study 25002300 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders about advice for dispensing artemether-lumefantrine (AL)
Number of subjects: 904
Study 25002300 — intervention group
Group type: COMPARATOR
Intervention: Standard dispensing practices without text message reminders
Number of subjects: 904
Study 22623230 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of omega-3 ethyl esters for 1 month
Number of subjects: 63
Study 22623230 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 63
Study 20736987 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet
Number of subjects: 0
Study 20736987 — intervention group
Group type: COMPARATOR
Intervention: Probiotic preparation
Number of subjects: 0
Study 20736987 — intervention group
Group type: COMPARATOR
Intervention: Synbiotic preparation
Number of subjects: 0
Study 19353351 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate combination (SFC)
Number of subjects: 0
Study 19353351 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 15716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day (administered bid)
Number of subjects: 99
Study 15716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 99
Study 15716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 99
Study 15716083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to levetiracetam
Number of subjects: 99
Study 12830369 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ibandronate
Number of subjects: 73
Study 12830369 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 73
Study 12830369 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 73
Study 12830369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ibandronate groups
Number of subjects: 73
Study 11154059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture treatment
Number of subjects: 330
Study 11154059 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 330
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms of hypericin (H)
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: 526 micrograms of pseudohypericin (PH)
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 micrograms of hypericin (H)
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,578 micrograms of pseudohypericin (PH)
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of hypericin and pseudohypericin
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Hypericum extract
Number of subjects: 13
Study 8878586 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of Hypericum extract
Number of subjects: 13
Study 1904750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ritanserin
Number of subjects: 12
Study 1904750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg ritanserin
Number of subjects: 12
Study 1904750 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 12
Study 1904750 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ritanserin
Number of subjects: 12
Study 1904750 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12
Study 1904750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6309882 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole
Number of subjects: 0
Study 6309882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6309882 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole (chronic administration)
Number of subjects: 0
Study 31714592 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT to postchemotherapy tumor volume (study arm)
Number of subjects: 309
Study 31714592 — intervention group
Group type: COMPARATOR
Intervention: TRT to prechemotherapy tumor volume (control arm)
Number of subjects: 309
Study 31714592 — intervention group
Group type: EXPERIMENTAL
Intervention: Study arm (TRT to postchemotherapy tumor volume)
Number of subjects: 309
Study 31714592 — intervention group
Group type: COMPARATOR
Intervention: Control arm (TRT to prechemotherapy tumor volume)
Number of subjects: 309
Study 30489326 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial stapled hemorrhoidopexy (group 1)
Number of subjects: 300
Study 30489326 — intervention group
Group type: COMPARATOR
Intervention: Circumferential stapled hemorrhoidopexy (group 2)
Number of subjects: 300
Study 27752830 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 40
Study 26720308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ADT
Number of subjects: 1134
Study 26720308 — intervention group
Group type: COMPARATOR
Intervention: Continuous ADT
Number of subjects: 1134
Study 24864639 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of 2% prilocaine
Number of subjects: 45
Study 24864639 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of 2% prilocaine + 8 mg of dexamethasone (2 ml)
Number of subjects: 45
Study 24864639 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg 0.5% levobupivacaine
Number of subjects: 45
Study 22274595 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon (PMTO)
Number of subjects: 110
Study 22274595 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention condition
Number of subjects: 110
Study 19619284 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-review group intervention (8 sessions)
Number of subjects: 0
Study 19619284 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 0
Study 17299059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 276
Study 17299059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 276
Study 17299059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 17299059 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label adalimumab 40 mg every other week
Number of subjects: 276
Study 15214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour (3 g of lysine per kilogram for three months)
Number of subjects: 264
Study 15214257 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour without fortification
Number of subjects: 264
Study 11225566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 10
Study 10223239 — intervention group
Group type: EXPERIMENTAL
Intervention: C + D + T (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2, Tamoxifen 20 mg/day)
Number of subjects: 56
Study 10223239 — intervention group
Group type: COMPARATOR
Intervention: C + D (Carboplatin 300 mg/m2, Dacarbazine 1 g/m2)
Number of subjects: 56
Study 10223239 — intervention group
Group type: EXPERIMENTAL
Intervention: C + D + T
Number of subjects: 56
Study 10223239 — intervention group
Group type: COMPARATOR
Intervention: C + D
Number of subjects: 56
Study 8536512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme substitution preparation
Number of subjects: 20
Study 8536512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2571460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vecuronium
Number of subjects: 12
Study 2571460 — intervention group
Group type: COMPARATOR
Intervention: Hourly boluses of vecuronium
Number of subjects: 12
Study 1069595 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus BCG
Number of subjects: 44
Study 1069595 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 44
Study 29458056 — intervention group
Group type: EXPERIMENTAL
Intervention: Light or moderate alcohol consumption (≤1 drink/day for women and 1 to 2 drinks/day for men)
Number of subjects: 0
Study 29458056 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking (>4 drinks/day)
Number of subjects: 0
Study 29458056 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine consumption before or during the evening meal
Number of subjects: 0
Study 27587469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation + ipilimumab
Number of subjects: 18
Study 27587469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (single-dose)
Number of subjects: 18
Study 27587469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 18
Study 24657311 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical imbalance test feedback (bogus biological test results)
Number of subjects: 0
Study 24657311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving chemical imbalance test feedback)
Number of subjects: 0
Study 22875102 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 47
Study 22875102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21077567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts to left‐turn encroachment incidents
Number of subjects: 36
Study 18690838 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 120mg bid
Number of subjects: 2854
Study 18690838 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2854
Study 16330887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI)
Number of subjects: 16000
Study 16330887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) after 2-3 years of tamoxifen
Number of subjects: 16000
Study 16330887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing aromatase inhibitors (AI) after 5 years of tamoxifen
Number of subjects: 16000
Study 16330887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical unrestricted label for AI
Number of subjects: 16000
Study 11881981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg single-dose and 12 days repeated-dose)
Number of subjects: 20
Study 9662319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter/intravaginal dinoprostone 4 mg every 4 hours
Number of subjects: 127
Study 9662319 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol 25 microg every 4 hours
Number of subjects: 127
Study 8148679 — intervention group
Group type: EXPERIMENTAL
Intervention: Self monitoring of peak flow
Number of subjects: 0
Study 8148679 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 0
Study 8148679 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with existing peak flow meters
Number of subjects: 0
Study 3342655 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxemia (SaO2 80%)
Number of subjects: 20
Study 3342655 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 20
Study 3342655 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 20
Study 3342655 — intervention group
Group type: COMPARATOR
Intervention: SaO2 85%
Number of subjects: 20
Study 3342655 — intervention group
Group type: COMPARATOR
Intervention: SaO2 90%
Number of subjects: 20
Study 2254832 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teeth (supragingival plaque removed)
Number of subjects: 2
Study 2254832 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (supragingival plaque not removed)
Number of subjects: 2
Study 2254832 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between control and experimental teeth
Number of subjects: 2
Study 947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone
Number of subjects: 283
Study 947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent combination of the same five drugs given in courses of 5 days repeated every 4 weeks
Number of subjects: 283
Study 947510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin as a single agent every 3 weeks
Number of subjects: 283
Study 31599746 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT group (continued DAPT)
Number of subjects: 87
Study 31599746 — intervention group
Group type: COMPARATOR
Intervention: Aspirin group (discontinued thienopyridines for 1 week)
Number of subjects: 87
Study 28369670 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA) program (n = 766)
Number of subjects: 1535
Study 28369670 — intervention group
Group type: COMPARATOR
Intervention: Health education program (n = 769)
Number of subjects: 1535
Study 25627357 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 458
Study 25627357 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 458
Study 23774986 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 201
Study 23774986 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 201
Study 21148266 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral long-term standardized resistance training (RES(O), n = 11)
Number of subjects: 36
Study 21148266 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with simultaneous electro-stimulation (RES(E), n = 11, 100 Hz, biphasic symmetrical wave, 400 µs)
Number of subjects: 36
Study 21148266 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n = 14)
Number of subjects: 36
Study 20301883 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (25 mg/day for 20 days) in Group A (smoking patients)
Number of subjects: 23
Study 20301883 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy (25 mg/day for 20 days) in Group B (non-smoking patients)
Number of subjects: 23
Study 17940723 — intervention group
Group type: COMPARATOR
Intervention: Treatment slowing atrophy rate by 30%
Number of subjects: 33
Study 14996869 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 80
Study 14996869 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 80
Study 14996869 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological evaluation
Number of subjects: 80
Study 14996869 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes
Number of subjects: 80
Study 11435237 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV (n = 15)
Number of subjects: 30
Study 11435237 — intervention group
Group type: COMPARATOR
Intervention: PCV (n = 15)
Number of subjects: 30
Study 9736234 — intervention group
Group type: COMPARATOR
Intervention: Conventional management at a hospital ward
Number of subjects: 38
Study 9736234 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment partly in a training apartment with problem-based education and special therapeutic support
Number of subjects: 38
Study 9736234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both management regimens (Conventional and Training Apartment)
Number of subjects: 38
Study 9736234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with poor glycaemic control (mean HbA1c >8.3%)
Number of subjects: 38
Study 9736234 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial risk factors (fathers' emotional responses)
Number of subjects: 38
Study 7518982 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 48
Study 7518982 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 48
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 75 mg kg‐1
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 25 mg kg‐1
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg kg‐1
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg kg‐1
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4-0.5 mg kg‐1
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (all doses)
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (all doses)
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of both premedicants
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate and midazolam
Number of subjects: 248
Study 3190970 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 248
Study 31515843 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of 1.5 g of cefuroxime
Number of subjects: 18
Study 31515843 — intervention group
Group type: COMPARATOR
Intervention: Short-term infusion (STI) of 1.5 g of cefuroxime
Number of subjects: 18
Study 28108059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Group Therapy (CBGT)
Number of subjects: 108
Study 28108059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 108
Study 28108059 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 108
Study 28108059 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 108
Study 26077459 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic regimen of Traditional Chinese Medicine (TCM) rehabilitation
Number of subjects: 416
Study 26077459 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT) control group
Number of subjects: 416
Study 23528400 — intervention group
Group type: EXPERIMENTAL
Intervention: Licopid as immunocorrective agent
Number of subjects: 76
Study 23528400 — intervention group
Group type: COMPARATOR
Intervention: Antifungal and antimicrobial treatment, eubiotics and bacteriophages
Number of subjects: 76
Study 21782514 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 5 days followed by HMG
Number of subjects: 53
Study 21782514 — intervention group
Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 53
Study 19307034 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy x 1)
Number of subjects: 180